Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer

This article was originally published in The Tan Sheet

Executive Summary

New Alka-Seltzer Plus Children's Cold Medicine promises "fizzy, fresh cherry taste," "cold relief made just for kids" and "cold medicine kids can take with a smile." Free sample packaging, with a $1-off coupon, says the "effervescent medicines gently break up your child's worst cold symptoms, fast." The active ingredients are phenylpropanolamine, chlorpheniramine and dextromethorphan. The product is slated to reach store shelves in September. The suggested retail price for a box of 20 tablets is approximately $5 (1"The Tan Sheet" Aug. 9, In Brief)

You may also be interested in...



Bayer

Alka-Seltzer Plus Children's Cold Medicine shipping now to retailers. The first Alka-Seltzer product aimed specifically at children is described as more taste-oriented than the line's adult versions; the product is cherry-flavored. Packaging indications for treatment include stuffy nose, coughing, runny nose and sneezing. The product is free of alcohol and aspirin and contains no other analgesics

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel